Table 1 Clinicopathologic and molecular findings of YWHAE–NUTM2B/E and BCOR-ITD positive URCS and PMMTI.

1^abdf

5 mo/F

Back

URCS (0%)

YWHAE-NUTM2B/E

NED (55 mo)

N

N

S + adjuvant Ch (IVA)

2^abcf

4 mo/M

Pelvic

URCS (0%)

YWHAE-NUTM2B/E

DOD (3 mo)

N

Y (cerebellum)

S + adjuvant Ch

3^ac

10 mo/M

Flank

URCS (0%)

YWHAE-NUTM2B/E

NED (192 mo)

N

N

Neoadjuvant Ch (VACA)/>50% necrosis on resection path response

4^a

0 mo/M

Buttock/sacral-coccygeal

URCS (0%)

YWHAE-NUTM2B/E

DOD (12 mo)

N

Y

Ch

5^a

2 mo/F

Abd wall

URCS (0%)

YWHAE

N/A

N/A

N/A

6^bdf

0 mo/M

Back

URCS (0%)

BCOR ITD (66 bp)

DOD (2 mo)

N

N

Ch (VAIA)/ No response to Ch

7^bdf

0 mo/F

Pelvic

URCS (0%)

BCOR ITD (66 bp)

DOD (26 mo)

Y

Y

Ch (IVA/IVE/IVADo/cisplatin) + S

8^bdf

3 mo/F

Jaw

URCS (0%)

BCOR ITD (66 bp)

DOD (8 mo)

N

N

Ch (VAC) + RT + S

9^bf

11 mo/M

Chest wall

URCS (0%)

BCOR ITD (96 bp)

NED (54 mo)

N

N

S + Ch (VAIA)

10^bdf

5 mo/M

Larynx

URCS (5%)

BCOR ITD (99 bp)

DOD (62 mo)

Y

Y

S + Ch (VA, then ID)

11^bf

5 mo/M

RP/pelvis

URCS (5%)

BCOR ITD (n/a)

DOD (30 mo)

Y

N

S + Ch (IVADo) + S

12^bf

10 mo/M

Para-vertebral

URCS (0%)

BCOR ITD (99 bp)

DOD (7 mo)

N

N

S + Ch (IVADo/IVE) + RT

13^b

11 mo/F

Pre-sacral

URCS (0%)

BCOR ITD (129 bp)

DOD (13 mo)

N

Y (multiple brain mets)

Ch (VAC/IE) + S + brachytherapy/response to Ch: 90% reduction in tumor size

14^b

6 mo/F

Intra-abd

URCS (0%)

BCOR ITD (n/a)

DOD (53 mo)

Y

N

S + Ch (VAC)

15^b

6 mo/F

Abd wall

URCS (10%)

BCOR ITD (93 bp)

DOD (6 mo)

N

Y (B, ST, Lung)

Ch

16^b

2/M

Abd/pelvic

URCS (0%)

BCOR ITD (93 bp)

N/A

N/A

N/A

17^b

19 mo/M

Brain, CPA/post fossa

URCS (0%)

BCOR ITD (126 bp)

AWD (56 mo)

Y

N

S + Ch + RT

18^bdf

0 mo/F

Chest wall post med

URCS (10%)

BCOR ITD (93 bp)

N/A

N/A

N/A

19^e

16/M

Scapula

URCS (0%)

BCOR ITD (n/a)

N/A

N/A

N/A

20^e

17/M

Paraspinal

URCS (10%)

BCOR ITD (n/a)

NED (4 mo)

N

N

S + Ch (MAP)

21^b

11 mo/F

Intracranial extra-axial

PMMTI (90%)

BCOR ITD (n/a)

N/A

N/A

N/A

22^bdf

2 mo/M

Para-spinal

PMMTI (90%)

BCOR ITD (96 bp)

NED (46 mo)

Y

Y

Ch (VA, then IVA) + S

23^bf

4 mo/F

Para-vertebral

PMMTI (30%)

BCOR ITD (120 bp)

AWD (120 mo)

Y

Y

S + Ch (VA, the IVA)

24^bf

9 mo/F

Abd wall

PMMTI (90%)

BCOR ITD (96 bp)

AWD (5 mo)

Y

N

N/A

25^b

10 mo/M

Intra-thoracic

PMMTI (90%)

BCOR ITD (96 bp)

DOD (16 mo)

Y

Y

S; Ch (ICE) + hyperthermia for recurrence/no path response

26^b

12 mo/F

Ankle

PMMTI (90%)

BCOR ITD (96 bp)

DOC (11 mo)

Y

Y (tibia, inguinal LN)

27^bf

0 mo/M

Neck

PMMTI (80%)

BCOR ITD (66 bp)

AWD (4 mo)

Y

N

S + adjuvant Ch

28^e

12 mo/M

RP/intra-abd

PMMTI (90%)

BCOR ITD (n/a)

DOD (12 mo)

N

Y

Ch (IVA, VACA, irinotecan, temozolomide)/progress on treatment

29^bf

3 mo/M

RP

PMMTI (90%)

BCOR ITD (96 bp)

DOD (3 mo)

N

N

Ch (IVADo)

30^b

12 mo/M

Intraspinal L1-L5

PMMTI (90%)

BCOR ITD (96 bp)

NED (24 mo)

N

N

S + Ch

31^b

11 mo/F

Orbit

PMMTI (80%)

BCOR ITD (96 bp)

N/A

N/A

N/A

32^bf

6 mo/M

RP/para-vertebral

PMMTI (40%)

BCOR ITD (n/a)

N/A

N/A

N/A

33^bf

10 mo/F

Abd mass

PMMTI (40%)

BCOR ITD (63 bp)

N/A

N/A

N/A